[go: up one dir, main page]

SG11201707905WA - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use - Google Patents

Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Info

Publication number
SG11201707905WA
SG11201707905WA SG11201707905WA SG11201707905WA SG11201707905WA SG 11201707905W A SG11201707905W A SG 11201707905WA SG 11201707905W A SG11201707905W A SG 11201707905WA SG 11201707905W A SG11201707905W A SG 11201707905WA SG 11201707905W A SG11201707905W A SG 11201707905WA
Authority
SG
Singapore
Prior art keywords
polycyclic
pharmaceutical use
carbamoylpyridone compounds
carbamoylpyridone
compounds
Prior art date
Application number
SG11201707905WA
Inventor
Zhenhong R Cai
Haolun Jin
Scott E Lazerwith
Hyung-Jung Pyun
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55754453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201707905W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201707905WA publication Critical patent/SG11201707905WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201707905WA 2015-04-02 2016-04-01 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use SG11201707905WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142338P 2015-04-02 2015-04-02
PCT/US2016/025740 WO2016161382A1 (en) 2015-04-02 2016-04-01 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Publications (1)

Publication Number Publication Date
SG11201707905WA true SG11201707905WA (en) 2017-10-30

Family

ID=55754453

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707905WA SG11201707905WA (en) 2015-04-02 2016-04-01 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Country Status (20)

Country Link
US (1) US9630978B2 (en)
EP (3) EP3736274A1 (en)
JP (2) JP6402259B2 (en)
KR (2) KR20190057158A (en)
CN (2) CN110790773A (en)
AU (3) AU2016244035B2 (en)
BR (1) BR112017020837A2 (en)
CA (1) CA2980362C (en)
EA (1) EA201791872A1 (en)
ES (2) ES2837383T3 (en)
HK (1) HK1249103B (en)
IL (1) IL254552A0 (en)
MX (1) MX2017012393A (en)
NZ (1) NZ735575A (en)
PL (1) PL3277691T3 (en)
PT (2) PT3277691T (en)
SG (1) SG11201707905WA (en)
SI (2) SI3277691T1 (en)
TR (1) TR201905009T4 (en)
WO (1) WO2016161382A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344879B (en) 2012-12-21 2017-01-11 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
TWI738321B (en) * 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
LT3236972T (en) 2014-12-26 2021-11-10 Emory University ANTIVIRAL N4-HYDROXICITIDINE DERIVATIVES
CA2980362C (en) * 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
LT3706762T (en) 2017-12-07 2024-12-27 Emory University N4-HYDROXYCYTIDINE AND ITS DERIVATIVES AND RELATED ANTIVIRAL USES
CN110526930B (en) * 2018-05-23 2022-06-03 莫云芬 anti-HIV (human immunodeficiency virus) sulfur-containing polycyclic-hydroxypyridone formamide analogue and application thereof
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
AU2019277548B2 (en) 2018-05-31 2023-12-14 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
SI3938047T1 (en) * 2019-03-22 2022-10-28 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (en) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Anellated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine-7-carboxamides - integrase inhibitors, methods for preparing and using thereof
TW202120510A (en) * 2019-11-13 2021-06-01 大陸商上海拓界生物醫藥科技有限公司 Novel tetracyclic heterocyclic compounds and pharmaceutical use thereof
JPWO2021107066A1 (en) 2019-11-28 2021-06-03
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
KR20230079137A (en) * 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 Crosslinked Tricyclic Carbamoylpyridone Compounds and Uses Thereof
CN114426540B (en) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 Pyrido [1,2-a ] pyrazine-1, 8-dione prodrug derivatives, preparation method and application thereof
TW202227445A (en) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 Use of inhibiting genetically defective hiv virus
PT4196479T (en) 2021-01-19 2024-01-03 Gilead Sciences Inc SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND THEIR USES
TWI856796B (en) 2022-04-06 2024-09-21 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN115015310B (en) * 2022-05-23 2024-12-10 宁波大学 A method for analyzing thiol compounds

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
NZ512184A (en) 1998-12-25 2003-08-29 Shionogi & Co Aromatic heterocycle compounds having HIV integrase inhibiting activities
EP1297834A4 (en) 2000-06-14 2007-05-09 Shionogi & Co Inhibitor for enzyme having two divalent metal ions as active centers
WO2003016275A1 (en) 2001-08-10 2003-02-27 Shionogi & Co., Ltd. Antiviral agent
CZ2004442A3 (en) 2001-10-03 2005-03-16 Ucb, S.A. Pyrrolidinone derivatives
EP1441735B1 (en) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
AU2003267098B2 (en) 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
SI1564210T1 (en) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
JP4996241B2 (en) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド Compositions and methods for combination antiviral therapy
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CA2554120A1 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors
EP1725535A4 (en) 2004-03-09 2009-11-25 Merck & Co Inc INHIBITORS OF HIV INTEGRASE
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
JP2008508291A (en) 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド Nucleoside phosphonate conjugates as anti-HIV agents
WO2006030807A1 (en) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (en) * 2005-02-21 2013-10-16 塩野義製薬株式会社 Bicyclic carbamoylpyridone derivatives having HIV integrase inhibitory activity
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
AU2006272521A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
EA018544B1 (en) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Method for treating retroviral infection
JP2009525261A (en) 2006-02-01 2009-07-09 日本たばこ産業株式会社 6- (3-Chloro-2-fluorobenzyl) -1-[(2S) -1-hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxo for the treatment of retroviral infections Use of -1,4-dihydroquinoline-3-carboxylic acid or a salt thereof
CN101437801B (en) 2006-03-06 2013-02-06 日本烟草产业株式会社 Process for preparing 4-oxoquinoline compounds
MX2008011457A (en) 2006-03-06 2008-09-24 Japan Tobacco Inc Method for producing 4-oxoquinoline compound.
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
CN105503721A (en) 2006-09-12 2016-04-20 吉里德科学公司 Process and intermediates for preparing integrase inhibitors
JP2010506913A (en) 2006-10-18 2010-03-04 メルク エンド カムパニー インコーポレーテッド HIV integrase inhibitor
EP2118082B1 (en) 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
AU2008270634B2 (en) 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
CA2692101A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
AR068403A1 (en) 2007-09-11 2009-11-18 Gilead Sciences Inc PROCESS AND INTERMEDIARIES FOR THE PREPARATION OF INTEGRASA INHIBITORS
KR20100097156A (en) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 Inhibitors of human immunodeficiency virus replication
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2010011813A1 (en) 2008-07-23 2010-01-28 Alkermes, Inc. Complex of trospium and pharmaceutical compositions thereof
SG192550A1 (en) 2008-07-25 2013-08-30 Viiv Healthcare Co Chemical compounds
US8183372B2 (en) 2008-07-25 2012-05-22 Shionogi & Co., Ltd. Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2448766T3 (en) 2008-07-25 2014-03-17 Viiv Healthcare Company Dolutegravir prodrugs
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2376080B1 (en) 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (en) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 Process for pyrone and pyridone derivatives
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EA032868B1 (en) 2010-01-27 2019-07-31 Вайв Хелткер Компани Combination for treating hiv infection
PH12012501689A1 (en) 2010-02-26 2012-11-05 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor
TWI582097B (en) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 Process for preparing carbamoylpyridone derivatives and intermediates
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
SG186820A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids
BR112012033689A2 (en) 2010-07-02 2019-09-24 Gilead Sciences Inc 2-quinolinyl acetic acid derivatives as antiviral HIV compounds
ES2608377T3 (en) 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Method of preparing a compound that has HIV integrase inhibitory activity
CN103228653B (en) 2010-09-24 2016-03-16 盐野义制药株式会社 The prodrug of the polycyclic carbamoylpyridone derivative be substituted
ES2615734T3 (en) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (en) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 Antiviral compound
EP2742051B1 (en) 2011-09-14 2016-10-12 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
BR112014008896A2 (en) 2011-10-12 2017-04-18 Shionogi & Co polycyclic pyridone derivative having integrase inhibitory activity
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
MX2014005002A (en) 2012-04-20 2014-07-09 Gilead Sciences Inc Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection.
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
SG11201503807TA (en) 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
MX344879B (en) * 2012-12-21 2017-01-11 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20160000721A1 (en) 2012-12-21 2016-01-07 Merck Sharp & Dohme Corp. Gastro-retentive formulations
RU2015131006A (en) * 2012-12-27 2017-01-30 Джапан Тобакко Инк. SUBSTITUTED SPIROPIRIDO [1,2-a] PYRASINE DERIVATIVE AND ITS USE IN MEDICINE AS A HUMAN IMMUNODEFICIENCY (HIV) VIRUS INTEGRASE INHIBITOR
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
LT3019503T (en) * 2013-07-12 2017-11-27 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (en) * 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX367057B (en) 2013-09-27 2019-08-02 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors.
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI738321B (en) * 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2980362C (en) * 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Also Published As

Publication number Publication date
BR112017020837A2 (en) 2018-07-03
CN107531727B (en) 2019-11-29
EA201791872A1 (en) 2018-04-30
AU2016244035A1 (en) 2017-10-12
JP2018510168A (en) 2018-04-12
TR201905009T4 (en) 2019-05-21
SI3277691T1 (en) 2019-04-30
US9630978B2 (en) 2017-04-25
JP6402259B2 (en) 2018-10-10
ES2837383T3 (en) 2021-06-30
JP6745308B2 (en) 2020-08-26
SI3466490T1 (en) 2020-12-31
KR20170131672A (en) 2017-11-29
CA2980362C (en) 2020-02-25
AU2019283812A1 (en) 2020-01-16
MX2017012393A (en) 2018-02-21
JP2018188483A (en) 2018-11-29
KR101982431B1 (en) 2019-05-27
US20160289246A1 (en) 2016-10-06
AU2016244035B2 (en) 2018-11-01
CA2980362A1 (en) 2016-10-06
AU2018236826A1 (en) 2018-10-18
PT3466490T (en) 2020-12-24
PL3277691T3 (en) 2019-07-31
EP3466490B1 (en) 2020-10-21
CN107531727A (en) 2018-01-02
AU2018236826B2 (en) 2019-09-19
HK1249103B (en) 2020-02-07
KR20190057158A (en) 2019-05-27
NZ735575A (en) 2018-11-30
EP3736274A1 (en) 2020-11-11
EP3466490A1 (en) 2019-04-10
PT3277691T (en) 2019-05-16
CN110790773A (en) 2020-02-14
WO2016161382A1 (en) 2016-10-06
HK1248688A1 (en) 2018-10-19
EP3277691A1 (en) 2018-02-07
EP3277691B1 (en) 2019-01-30
ES2718410T3 (en) 2019-07-01
IL254552A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
IL254552A0 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL252532A0 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
GB201403093D0 (en) Therapeutic compounds and their use
ZA201802256B (en) Compounds and therapeutic uses thereof
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
IL250729B (en) Pyrazolothiazole compound and medicine comprising same
ZA201607919B (en) Dipicolylamine derivatives and their pharmaceutical uses
GB201406172D0 (en) Therapy and pharmaceutical composition
SG10202106375UA (en) Pharmaceutical compositions and use thereof
GB201413058D0 (en) Pharmaceutical agent
GB201517133D0 (en) New pharmaceutical use
GB201616767D0 (en) New pharmaceutical use
GB201517454D0 (en) New pharmaceutical use
GB201517132D0 (en) New pharmaceutical use
GB201702051D0 (en) New Pharmaceutical use
GB201508611D0 (en) New pharmaceutical use
GB201508613D0 (en) New pharmaceutical use
GB201507813D0 (en) New pharmaceutical use
GB201514770D0 (en) Compounds and their use
GB201513318D0 (en) Novel compounds and their use
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use